Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27927170 | 0.92 | ALDH1A1 (0.59) | LMNAMAPTALDH1A1THRBSLC6A5 | |
| SCHEMBL6599002 | 0.89 | ALDH1A1 (0.56) | LMNAMAPTGAAALDH1A1THRB | |
| SCHEMBL6599004 | 0.89 | ALDH1A1 (0.56) | LMNAMAPTGAAALDH1A1THRB | |
| SCHEMBL3547962 | 0.86 | ALDH1A1 (0.74) | LMNAMAPTGAAALDH1A1HPGD | |
| SCHEMBL6840537 | 0.85 | ALDH1A1 (0.53) | LMNAMAPTALDH1A1THRBSLC6A5 | |
| SCHEMBL30957484 | 0.85 | LMNA (0.69) | LMNAMAPTGAAALDH1A1THRB | |
| SCHEMBL3553731 | 0.85 | LMNA (0.69) | LMNAMAPTGAAALDH1A1THRB | |
| SCHEMBL7049102 | 0.84 | GAA (0.60) | LMNAMAPTGAAALDH1A1THRB | |
| SCHEMBL1810972 | 0.83 | ALDH1A1 (0.70) | LMNAMAPTALDH1A1THRBSLC6A5 | |
| SCHEMBL1846736 | 0.83 | TDP1 (0.71) | LMNAMAPTGAAALDH1A1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| CN-1938295-A | Imidazol-5-yl-anilinopyrimidines as cell proliferation inhibitors | ASTRAZENECA AB (SE) | 2007-03-28 | — | — | CN | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | LMNA 3296/4885MAPT 2115/4885GAA 171/4885 |
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | LMNA 988/4885MAPT 3632/4885GAA 64/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | LMNA 3477/4885MAPT 1986/4885GAA 163/4885 |
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | DGAT1, ACAT1, DGAT2 | LMNA 3790/4885MAPT 2472/4885GAA 244/4885 |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | LMNA 2990/4885MAPT 4713/4885GAA 3412/4885 |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT2, GPR119, DGAT1 | LMNA 3179/4885MAPT 2561/4885GAA 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.